Evidence map›Paper›PMID 42620250›Full record

ArticleResearch square2026

Multi-dimensional attention framework for personalised Alzheimer's disease progression prediction across sporadic and genetic risk cohorts.

Zhiyuan Song, Siyang Song, Isabel C H Clare, Elizabeth Head, Christy L Hom, Adam M Brickman, Sigan Hartley, Patrick J Lao, Frederick A Schmitt, Beau M Ances and 17 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Zhiyuan SongDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Siyang SongHBUG Lab, University of Exeter, EX4 4PY, Exeter, United Kingdom.
Isabel C H ClareDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Elizabeth HeadDepartment of Pathology & Laboratory Medicine, University of California, Irvine School of Medicine, Irvine, California, 92617, USA.
Christy L HomDepartment of Neurology, University of California, Irvine School of Medicine, Irvine, CA, 92617, USA.
Adam M BrickmanTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York City, NY, USA.
Sigan HartleyWaisman Center, University of Wisconsin Madison, Madison, WI, USA.
Patrick J LaoTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York City, NY, USA.
Frederick A SchmittKentucky College of Osteopathic Medicine, University of Pikeville, Pikeville, Kentucky, USA.
Beau M AncesWashington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Dana L TudorascuDepartment of Psychiatry, University of Pittsburgh, 3811 O'Hara St, Pittsburgh, PA, 15213, USA.
Sharon Krinsky-McHaleNew York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA.
Florence LaiCenter for Neuroimaging of Aging and Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02114, USA.
Herminia Diana RosasCenter for Neuroimaging of Aging and Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02114, USA.
Annie D CohenDepartment of Psychiatry, University of Pittsburgh, 3811 O'Hara St, Pittsburgh, PA, 15213, USA.
Michael RafiiKeck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.
Michael A YassaCenter for the Neurobiology of Learning and Memory, University of California, Irvine, CA, USA.
Sid O'BryantUniversity of North Texas Health Science Center, Fort Worth, TX, USA.
Joseph H LeeDepartment of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H. Sergievsky Center, Columbia University, New York, NY, 10032, USA.
Lauren PtomeyUniversity of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, Kansas, 66160, USA.
Benjamin L HandenDepartment of Psychiatry, University of Pittsburgh, 3811 O'Hara St, Pittsburgh, PA, 15213, USA.
Bradley T ChristianWaisman Center, University of Wisconsin Madison, Madison, WI, USA.
Mark MapstoneDepartment of Neurology, University of California, Irvine School of Medicine, Irvine, California, 92617, USA.
Sarah E MorganDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Shahid ZamanDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Alzheimer Biomarker Consortium – Down Syndrome
Dominantly Inherited Alzheimer Network

Funding

Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
NIA NIH HHS U19 AG032438
6 · The paper itself

Abstract

Alzheimer's disease progresses heterogeneously across diverse cohorts, yet current predictive models fail to capture this complexity while remaining clinically interpretable. Here we present a multi-dimensional attention framework that simultaneously captures both temporal dynamics and biomarker importance to predict disease progression across three fundamentally different populations: the general late-onset population using the Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) dataset (N=1669), cases with Down Syndrome-associated Alzheimer's disease using the Alzheimer's Biomarker Consortium - Down Syndrome (ABC-DS) dataset (N=396), and cases with autosomal dominant Alzheimer's disease using the Dominantly Inherited Alzheimer Network (DIAN) dataset (N=425). Trained on each dataset independently, our framework achieved multi-class Area Under the Receiver Operating Characteristic Curve (mAUC) values of 0.793 (TADPOLE), 0.680 (ABC-DS), and 0.902 (DIAN) when predicting individuals' future diagnostic status (cognitively normal/stable, mild cognitive impairment, or Alzheimer's disease) from their longitudinal biomarker history, outperforming conventional approaches. The model generates individual-specific attention maps revealing distinct biomarker importance over time. Transfer learning from TADPOLE-which included neuroimaging data-improved prediction performance on the imaging-free ABC-DS dataset from 0.680 to 0.771, demonstrating that disease mechanisms transcend both etiological boundaries and data modalities. Ultimately, this framework could enable precision medicine approaches for data-limited cohorts across the Alzheimer's disease spectrum.

Indexed as

Alzheimer's diseaseattention mechanismdeep learningdisease progression predictionDown syndrometransfer learning

Identifiers

PMID42620250
PMCPMC13484860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.